Bridge the gap

The need for harmonized regulatory and ethical standards for postmarketing observational studies

Hisashi Urushihara, Louise Parmenter, Shimon Tashiro, Kenji Matsui, Nancy Dreyer

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Drug safety issues do not respect national borders. Hence, addressing a safety question may necessitate globally coordinated efforts between regulatory authorities and market authorization holders (MAHs) to draw reliable conclusions. Regulatory authorities have shared responsibility with MAHs sponsoring postmarketing nonintervention studies in determining study goals and design. Their shared accountabilities include what will be investigated and how the data will be retrieved to ensure appropriate study quality required for regulatory decision making. The need for a harmonized framework and ethical standards for postmarketing observational studies is well recognized but has been lacking even among the United States, European Union, and Japan, which are so-called International Conference on Harmonisation (ICH) regions. A recent update of the Council for International Organizations of Medical Sciences International Ethical Guidelines for Health-Related Research Involving Humans provides further clarification on provisions for informed consent and the role of research ethics committees. However, without incorporation into legislative structures, the future impact of these guidelines is uncertain. This lack of harmonization leads to a complex and uncertain framework for ethical review and for participant informed consent, resulting in numerous inefficiencies in the regulatory postmarketing observational studies. The regulatory frameworks for postmarketing observational studies conducted under the auspices of regulatory agencies in the 3 regions are reviewed, with a focus on ethical requirements and opportunities for efficiencies.

Original languageEnglish
Pages (from-to)1299-1306
Number of pages8
JournalPharmacoepidemiology and Drug Safety
Volume26
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Observational Studies
Informed Consent
Ethical Review
Guidelines
Safety
Research Ethics Committees
Social Responsibility
European Union
Decision Making
Japan
Organizations
Health
Research
Pharmaceutical Preparations

Keywords

  • ethics
  • observational study
  • pharmacoepidemiology
  • postmarketing study
  • regulation

ASJC Scopus subject areas

  • Epidemiology
  • Pharmacology (medical)

Cite this

Bridge the gap : The need for harmonized regulatory and ethical standards for postmarketing observational studies. / Urushihara, Hisashi; Parmenter, Louise; Tashiro, Shimon; Matsui, Kenji; Dreyer, Nancy.

In: Pharmacoepidemiology and Drug Safety, Vol. 26, No. 11, 01.11.2017, p. 1299-1306.

Research output: Contribution to journalReview article

Urushihara, Hisashi ; Parmenter, Louise ; Tashiro, Shimon ; Matsui, Kenji ; Dreyer, Nancy. / Bridge the gap : The need for harmonized regulatory and ethical standards for postmarketing observational studies. In: Pharmacoepidemiology and Drug Safety. 2017 ; Vol. 26, No. 11. pp. 1299-1306.
@article{4bd16b61e71e486dacec139994cf253d,
title = "Bridge the gap: The need for harmonized regulatory and ethical standards for postmarketing observational studies",
abstract = "Drug safety issues do not respect national borders. Hence, addressing a safety question may necessitate globally coordinated efforts between regulatory authorities and market authorization holders (MAHs) to draw reliable conclusions. Regulatory authorities have shared responsibility with MAHs sponsoring postmarketing nonintervention studies in determining study goals and design. Their shared accountabilities include what will be investigated and how the data will be retrieved to ensure appropriate study quality required for regulatory decision making. The need for a harmonized framework and ethical standards for postmarketing observational studies is well recognized but has been lacking even among the United States, European Union, and Japan, which are so-called International Conference on Harmonisation (ICH) regions. A recent update of the Council for International Organizations of Medical Sciences International Ethical Guidelines for Health-Related Research Involving Humans provides further clarification on provisions for informed consent and the role of research ethics committees. However, without incorporation into legislative structures, the future impact of these guidelines is uncertain. This lack of harmonization leads to a complex and uncertain framework for ethical review and for participant informed consent, resulting in numerous inefficiencies in the regulatory postmarketing observational studies. The regulatory frameworks for postmarketing observational studies conducted under the auspices of regulatory agencies in the 3 regions are reviewed, with a focus on ethical requirements and opportunities for efficiencies.",
keywords = "ethics, observational study, pharmacoepidemiology, postmarketing study, regulation",
author = "Hisashi Urushihara and Louise Parmenter and Shimon Tashiro and Kenji Matsui and Nancy Dreyer",
year = "2017",
month = "11",
day = "1",
doi = "10.1002/pds.4269",
language = "English",
volume = "26",
pages = "1299--1306",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Bridge the gap

T2 - The need for harmonized regulatory and ethical standards for postmarketing observational studies

AU - Urushihara, Hisashi

AU - Parmenter, Louise

AU - Tashiro, Shimon

AU - Matsui, Kenji

AU - Dreyer, Nancy

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Drug safety issues do not respect national borders. Hence, addressing a safety question may necessitate globally coordinated efforts between regulatory authorities and market authorization holders (MAHs) to draw reliable conclusions. Regulatory authorities have shared responsibility with MAHs sponsoring postmarketing nonintervention studies in determining study goals and design. Their shared accountabilities include what will be investigated and how the data will be retrieved to ensure appropriate study quality required for regulatory decision making. The need for a harmonized framework and ethical standards for postmarketing observational studies is well recognized but has been lacking even among the United States, European Union, and Japan, which are so-called International Conference on Harmonisation (ICH) regions. A recent update of the Council for International Organizations of Medical Sciences International Ethical Guidelines for Health-Related Research Involving Humans provides further clarification on provisions for informed consent and the role of research ethics committees. However, without incorporation into legislative structures, the future impact of these guidelines is uncertain. This lack of harmonization leads to a complex and uncertain framework for ethical review and for participant informed consent, resulting in numerous inefficiencies in the regulatory postmarketing observational studies. The regulatory frameworks for postmarketing observational studies conducted under the auspices of regulatory agencies in the 3 regions are reviewed, with a focus on ethical requirements and opportunities for efficiencies.

AB - Drug safety issues do not respect national borders. Hence, addressing a safety question may necessitate globally coordinated efforts between regulatory authorities and market authorization holders (MAHs) to draw reliable conclusions. Regulatory authorities have shared responsibility with MAHs sponsoring postmarketing nonintervention studies in determining study goals and design. Their shared accountabilities include what will be investigated and how the data will be retrieved to ensure appropriate study quality required for regulatory decision making. The need for a harmonized framework and ethical standards for postmarketing observational studies is well recognized but has been lacking even among the United States, European Union, and Japan, which are so-called International Conference on Harmonisation (ICH) regions. A recent update of the Council for International Organizations of Medical Sciences International Ethical Guidelines for Health-Related Research Involving Humans provides further clarification on provisions for informed consent and the role of research ethics committees. However, without incorporation into legislative structures, the future impact of these guidelines is uncertain. This lack of harmonization leads to a complex and uncertain framework for ethical review and for participant informed consent, resulting in numerous inefficiencies in the regulatory postmarketing observational studies. The regulatory frameworks for postmarketing observational studies conducted under the auspices of regulatory agencies in the 3 regions are reviewed, with a focus on ethical requirements and opportunities for efficiencies.

KW - ethics

KW - observational study

KW - pharmacoepidemiology

KW - postmarketing study

KW - regulation

UR - http://www.scopus.com/inward/record.url?scp=85032678759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032678759&partnerID=8YFLogxK

U2 - 10.1002/pds.4269

DO - 10.1002/pds.4269

M3 - Review article

VL - 26

SP - 1299

EP - 1306

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 11

ER -